Apaf-1-interacting protein (APIP) was previously isolated as an inhibitor of mitochondrial cell death interacting with Apaf-1. Here, we report a hypoxia-selective antiapoptotic activity of APIP that induces the activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Stable expression of APIP in C2C12 (C2C12/APIP) cells suppressed cell death induced by hypoxia and etoposide. Unlike etoposide, however, APIP induces the sustained activation of AKT and ERK1/2 and the phosphorylation of caspase-9 during hypoxia. Inhibition of AKT and ERK1/2 activation by the treatments with phosphatidylinositol 3 0 -kinase and mitogen-activated protein kinase kinase (MEK)1/2 inhibitors sensitized C2C12/APIP cells to hypoxic cell death and abolished the hypoxia-induced phosphorylation of caspase-9. Further, overexpression of phosphorylation-mimic caspase-9 mutants (caspase-9-T125E and caspase-9-S196D), but not phosphorylation-defective caspase-9 mutants (caspase-9-T125A and caspase-9-S196A), effectively suppressed hypoxia-induced death of C2C12 cells. These results elucidate a novel Apaf-1-independent antiapoptotic activity of APIP during hypoxic cell death, inducing the sustained activation of AKT and ERK1/2 and leading to caspase-9 phosphorylation.
Cells undergo a variety of biological responses when they are placed under hypoxic condition, including activation of signaling pathways that regulate proliferation, angiogenesis and cell death. Hypoxic/ischemic trauma is a primary factor in the pathology of many diseases such as tumors. Therefore, the development of tolerance to hypoxia and resistance to apoptosis has been suggested to be a mechanism by which tumors become more malignant (Dang and Semenza, 1999) .
Hypoxia is able to activate extracellular signalregulated kinase (ERK)1/2 that stimulates cell growth and proliferation (Jiang et al., 2002; Mottet et al., 2003) . Also, activation of ERK pathway inhibits cell death induced by serum deprivation or matrix detachment, and can suppress caspase-3 activation even though cytochrome c is released from the mitochondria (Le Gall et al., 2000; Rytomaa et al., 2000) . Anti-apoptotic functions of ERK pathway are associated with the inhibition of caspase-9 through direct phosphorylation (Allan et al., 2003) . AKT, a key molecule of many receptor tyrosine kinase response pathways that are involved in cell proliferation, migration and inhibition of apoptosis, is also activated under hypoxic/ischemic condition (Chen et al., 2001; Jiang et al., 2002) . AKT directly phosphorylates and inhibits proapoptotic factors, such as Bad and caspase-9, and is transiently activated during hypoxia (Datta et al., 1997; Cardone et al., 1998; Romashkova and Makarov, 1999) . Moreover, it stimulates the phosphorylation of I kappa B Kinase cells (IKK) or cyclic AMP-responsive elementbinding protein (CREB) to increase the expression of genes promoting cell survival (Du and Montminy, 1998) . However, hypoxia-induced cell death is not well understood.
Recently, our group identified an Apaf-1-interacting protein (APIP). APIP functions to inhibit the intrinsic mitochondrial apoptosis pathway including etoposide, staurosporine and hypoxia-induced cell death (Cho et al., 2004) . APIP is also highly expressed in muscle and heart and accumulated in mouse muscle during ischemia. We further characterized the roles of APIP in cell death pathways and here provide signal-selective and Apaf-1-independent antiapoptotic activity of APIP. During hypoxia, APIP suppresses hypoxia-induced cell death by inducing the activation of AKT and ERK1/2, which inhibits caspase-9 activation via phosphorylation.
Previously, APIP was reported to function to reduce cell death triggered by mitochondrial signals and bind to Apaf-1 in vitro and in vivo. To further explore the inhibitory effects of APIP on hypoxia-induced cell death, we generated C2C12 mouse muscle cell lines that stably overexpressed APIP (C2C12/APIP). As expected, expression of APIP in C2C12 cells efficiently suppressed hypoxia-induced cell death (Figure 1a , Supplementary data Figure 1 ) and caspase-3-like activity (Figure 1b) .
Recently, AKT and ERK1/2 were reported to be phosphorylated under hypoxic/ischemic condition (Jiang et al., 2002) . Thus, we examined the activation Role of APIP in AKT and ERK1/2 activation D-H Cho et al of AKT, ERK1/2 and p38 under hypoxic condition. Consistently, Western blotting using anti-phosphospecific antibodies showed that the phosphorylation levels of AKT and ERK1/2 were slightly increased at 3 h and over the times during hypoxia of C2C12 cells, respectively (Figure 1c and d) . Compared to C2C12/neo cells, however, the phosphorylation levels of AKT and ERK1/2 were significantly increased and maintained higher until later times (10 h) during hypoxia of C2C12/ APIP cells. The level of phospho-p38 was not changed during hypoxia. Similar results were observed in other C2C12/APIP cell clones (data not shown). These results indicate that APIP functions to increase and sustain the activities of AKT and ERK1/2 during hypoxia. We then examined the domain of APIP suppressing hypoxic cell death. From ectopic expression analysis, APIP and its deletion mutant, APIP(70-204), suppressed hypoxic cell death ( Figure 1e ). Further, Western blotting showed that APIP(70-204) mutant is able to induce ERK1/2 activation during hypoxia (Figure 1e , insert). These results suggest that the middle and C-terminal region of APIP suppresses hypoxia-induced cell death and regulates kinase activity, distinct from its effects on etoposide-induced cell death. Next, we examined the contribution of APIPmediated activation of AKT and ERK1/2 to hypoxic cell death. Treatment of C2C12/neo cells with LY294002, an inhibitor of phosphatidylinositol 3 0 -kinase (PI3K) and AKT, increased hypoxia-induced cell death (32-47%), whereas PD98059, an inhibitor of mitogen-activated protein kinase kinase (MEK)1/2 and ERK1/2, did not ( Figure 2a, left panel) . However, each inhibitor potently sensitized C2C12/APIP cells to hypoxia-induced cell death, increasing the rates of cell death from 8 to 29% (3.6-fold) for PI3K inhibitor and from 8 to 17% (2-fold) for MEK1/2 inhibitor (Figure 2a, left panel) , suggesting that APIP inhibits hypoxia-induced cell death by activating AKT and ERK1/2. Inhibitions of hypoxia-induced phosphorylation of AKT or ERK1/2 were confirmed by Western blotting after treatment with LY294002 or PD98059 (Figure 2a, right panel) .
Similar experiments were performed using etoposide, DNA-damaging agent (Figure 2b ). Like hypoxia, APIP expression was sufficient to inhibit etoposide-induced death of C2C12 cells to control level. Unlike hypoxia, however, either LY294002 or PD98059 did not significantly sensitize etoposide-induced death of C2C12/ APIP cells (Figure 2b , left panel). In addition, Western blot analysis showed that in contrast to hypoxia, etoposide treatment did not induce the phosphorylation of AKT or ERK1/2 (Figure 2b , right panel), consistent with little effects of LY294002 or PD98059 on etoposide-induced cell death (Figure 2b, left panel) . These results suggest that, whereas APIP effectively inhibits both hypoxia-and etoposide-induced cell death, the inhibitory activity of APIP on hypoxic cell death is at least mediated through the activation of AKT and ERK1/2. The role of AKT in hypoxia-induced death of C2C12/APIP cells was further examined: whereas Figure 2 Inhibitors of AKT and ERK1/2 potentiate hypoxic death of C2C12/APIP cells. C2C12/neo (C) and C2C12/APIP (A) cells were incubated with LY294002 (LY, 50 mM, Biomol international, T420, Plymouth meeting, PA, USA) or PD98059 (PD, 40 mM, CNB, 513000, Madrid, Spain) and then left untreated (CTRL) or exposed to either hypoxia (a) or etoposide (40 mM, Sigma, E1383, St Louis, MO, USA) (b) for 15 h. Bars (means7s.d.) (n ¼ 5) depict cell viability. Cell extracts were prepared and examined with Western blotting using the indicated antibodies.
Role of APIP in AKT and ERK1/2 activation D-H Cho et al ectopic expression of AKT reduced hypoxia-induced death of C2C12/neo cells, dominant-negative AKT sensitized C2C12/APIP cells to hypoxic cell death, further supporting that AKT activity in C2C12/APIP cells is required to suppress hypoxic cell death (Supplementary data Figure 2) .
Caspase-9 initiates Apaf-1-mediated activation of caspase cascade and transduces the injury signaling caused by hypoxia. Caspase-9 is also negatively regulated by the phosphorylation on Ser 196 and Thr 125 by AKT and ERK1/2, respectively. Thus, we addressed whether APIP-mediated activation of AKT and ERK1/ 2 could phosphorylate caspase-9. Interestingly, the acidic phase-migrating caspase-9, probably phosphorylated caspase-9, was apparently observed only in C2C12/APIP cells but not in C2C12/neo cells exposed to hypoxia as examined with Western blotting following two-dimensional polyacrylamide gel electrophoresis (Figure 3a , middle panel). However, this modification almost disappeared by the treatments of C2C12/APIP cells with LY294002 and PD98059 during hypoxia (Figure 3a , lower panel) and was not observed in C2C12/APIP cells exposed to etoposide (data not shown).
Also, we directly examined hypoxia-induced phosphorylation of caspase-9 using phospho-specific antibody. As phospho-specific antibody of mouse caspase-9 is not available, we instead transfected human caspase-9 into C2C12/neo or C2C12/APIP cells and then exposed to hypoxia (Figure 3b) . Western blotting using an antibody recognizing phospho-Thr 125 of caspase-9 detected the phosphorylated caspase-9 in C2C12/APIP cells. Further, enzymatic assay showed that hypoxiainduced activation of caspase-9 was suppressed in C2C12/APIP cells (Figure 3c ). These results suggest that APIP functions to ensure the phosphorylation of caspase-9 by increasing and sustaining the activities of AKT or EKR1/2 during hypoxic damages.
To further explore the phosphorylation effects of caspase-9 on hypoxic cell death, we generated phosphorylation-mimic caspase-9 mutants by replacing Ser 196 with Asp (caspase-9-S196D) and Thr 125 with Glu (caspase-9-T125E), and phosphorylation-defective caspase-9 mutants replacing Ser 196 with Ala (caspase-9-S196A) and Thr 125 with Ala (caspase-9-T125A). C2C12/neo and C2C12/APIP cells were transiently transfected with these constructs and then exposed to hypoxia (Figure 4a ) or etoposide (Figure 4b ). Ectopic expression of phosphorylation-mimic caspase-9 mutants, casapase-9-T125E and caspae-9-S196D, significantly inhibited hypoxia-induced death of C2C12/neo cells, decreasing death rates from 47 to 26 and 16%, respectively, which is similar with death rates of C2C12/ APIP cells (Figure 4a ). However, these phosphorylation-mimic caspase-9 mutants did not suppress cell death triggered by etoposide (Figure 4b ). In addition, the expression of phosphorylation-defective caspase-9 mutants, caspase-9-T125A and caspase-9-S196A, failed to show any inhibitory effects on cell death triggered by hypoxia or etoposide. These results indicate that the phosphorylation of caspase-9 is important to suppress hypoxic cell death, which is believed to be controlled by APIP through the activation of AKT and ERK1/2.
Our previous work showed that APIP binds to Apaf-1 and inhibits the intrinsic cell death, postulating that the antiapoptotic activity of APIP lies in its binding ability to Apaf-1 (Cho et al., 2004) . From subsequent analyses, however, we observed that the overexpression of APIP further suppressed hypoxia-induced death of Apaf-1(À/ À) mouse embryonic fibroblasts (MEF) cells (Supplementary data Figure 3) . Here, we provide additional signal-selective antiapoptotic activity of APIP that is Apaf-1-independent and induces sustained activation of AKT and ERK1/2 during hypoxia. Thus, APIP appears to play a dual role in the regulation of mitochondrial cell death. First, APIP binds to Apaf-1 to block the (PD, 40 mM) . Cell extracts applied to pH3-10 IPG strips (Amersham Biosciences, 17-6001-10, Piscataway, NJ, USA) were separated by isoelectric focusing and then analysed by Western blotting using anti-caspase-9 antibody. (b) C2C12/neo (C) and C2C12/APIP cells (A) were transfected with pHA-caspase-9 for 24 h and then left untreated (CTRL) or exposed to hypoxia for 15 h. Western blotting was performed using anti-phospho-caspase-9 (Cell Signaling, No. 2226) or anti-HA antibody. (c) Caspase-9 activity was measured using LEHD-AFC (Enzyme System Products, 199445) as described in Figure 1b Role of APIP in AKT and ERK1/2 activation D-H Cho et al recruitment of caspase-9 into apoptosome, inhibiting the mitochondrial cell death in cells exposed to cytotoxic drugs including etoposide. Second, APIP increases and sustains the activities of AKT and ERK1/2 under hypoxic/ischemic condition, inhibiting the activation of caspase-9 through phosphorylation. These distinct activities seem to be assigned to different domains of APIP. As shown in the previous report (Cho et al., 2004) , core domain of APIP spanning the common region of APIP and APIP2 was sufficient to suppress etoposide-induced cell death. However, the C-terminal region of APIP rather than core domain is required for the activation of ERK1/2 during hypoxia (Figure 1e ). For the explanations of how APIP induces the increased and long-lasting activities of AKT and ERK1/2, we examined aldolase activity of APIP, as APIP shows high homology with aldolase domains of many species (Yanez et al., 2005) . Aldolase A is highly expressed during hypoxia. However, we could not detect aldolase-like activity of APIP using enzymatic assays (data not shown). We speculate that APIP directly activates PI3K or upstream of PI3K, because the protective effect of APIP on hypoxia was abolished by PI3K inhibitor. APIP-interacting protein(s) functioning at the upstream of AKT remain for characterization.
The increased expression of APIP in mouse muscle during ischemia/hypoxia is believed to be a necessary step protecting cells from damages (Cho et al., 2004) . APIP mRNA was also induced in HepG2 cells, but not in HeLa, NIH3T3 and HEK293T cells (data not shown). Hypoxia-inducible factor-1 (HIF-1)a is induced during hypoxia and contributes to cell survival through the activation of survival genes and anaerobic metabolism (Chen et al., 2003) . We found a hypoxia-response element ( þ 35 GCCGTGCG þ 42 ) on 5 0 untranslated region of APIP gene. However, overexpression of HIF-1a failed to induce APIP during normoxia or hypoxia (data not shown), suggesting that HIF-1a is not sufficient to induce APIP expression. Additional transcription factor(s) may be required to regulate APIP expression during hypoxia.
AKT and ERK modulate the function of numerous proteins involved in cell growth and cell survival. Several proapoptotic molecules, such as Bad, ASK1 and caspase-9, are inactivated through the phosphorylation by AKT and ERK1/2. During hypoxic damages, APIP-mediated activation of AKT and ERK1/2 appears to suppress ischemic cell death by phosphorylating caspase-9. Antiapoptotic effects of phosphorylationmimic caspase-9 mutants on hypoxic cell death indicate that caspase-9 is an important downstream of AKT and ERK1/2 during hypoxic damages. Taken together, these results indicate that during hypoxic damages, APIP displays Apaf-1-independent inhibitory activities by inducing the sustained activation of AKT and ERK1/2 and subsequent phosphorylation of caspase-9. Thus, we propose that depending on cell death signals, APIP functions to inhibit Apaf-1-mediated cell death by binding to Apaf-1 or to inhibit Apaf-1-independent activation of caspase-9 by increasing the activities of AKT and ERK1/2, providing 'a double-locking model' in caspase-9-mediated cell death.
